<DOC>
	<DOCNO>NCT00286845</DOCNO>
	<brief_summary>A previous preliminary study perform Vanderbilt University funding Leukemia Society America demonstrate response leukemia cell vitro chemotherapeutic agent idarubicin microculture kinetic assay apoptosis ( MiCK assay ) predict survival patient newly diagnose acute myeloid leukemia ( AML ) . In previous study , achievement complete response ( CR ) induction therapy idarubicin cytarabine use clinical indicator determine whether leukemia specimen take prior treatment sensitive sensitive MiCK assay . This group patient follow 7 year long term survival rate show responses MiCK assay idarubicin cytarabine predict survival . In present proposal separate group patient newly diagnose AML recruit provide leukemia cell sample use establish criterion sensitivity non-sensitivity idarubicin cytarabine MiCK assay . The achievement CR use determine vitro sensitivity do previous study . With vitro sensitivity determine propose study , long term survival patient previous study analyze prospectively . The propose study expect approximate duration one year . Patient population include newly diagnose AML patient de novo AML AML arise previously diagnose myelodysplastic syndrome . The study include patient previously treat leukemia relapse</brief_summary>
	<brief_title>Use MiCK Assay Apoptosis AML</brief_title>
	<detailed_description>A previous preliminary study perform Vanderbilt University funding Leukemia Society America demonstrate response leukemia cell vitro chemotherapeutic agent idarubicin microculture kinetic assay apoptosis ( MiCK assay ) predict survival patient newly diagnose acute myeloid leukemia ( AML ) . In previous study , achievement complete response ( CR ) induction therapy idarubicin cytarabine use clinical indicator determine whether leukemia specimen take prior treatment sensitive sensitive MiCK assay . This group patient follow 7 year long term survival rate show responses MiCK assay idarubicin cytarabine predict survival . In present proposal separate group patient newly diagnose AML recruit provide leukemia cell sample use establish criterion sensitivity non-sensitivity idarubicin cytarabine MiCK assay . The achievement CR use determine vitro sensitivity do previous study . With vitro sensitivity determine propose study , long term survival patient previous study analyze prospectively . STUDY DESIGN 1 . Recruit patient assign unique number time sample collection . All sample data record unique number . The key unique number assign patient kept principal investigator Vanderbilt . 2 . After obtain informed consent , collect specimens patient whose induction therapy include cytarabine idarubicin . Collect ship DiaTech overnight courier fifty ( 50 ) bone marrow peripheral blood [ available , bone marrow peripheral blood ] specimens newly diagnose patient AML . Newly diagnose AML patient include diagnose de novo arise previously diagnose myelodysplastic syndrome , include patient previously treat leukemia relapse . An adequate specimen analysis contain sufficient number viable leukemia cell perform MiCK assay 7 dos cytarabine 7 dos idarubicin.. 3 . Each patient 's clinically recognize predictor leukemia treatment outcome record . These predictor include age , sex , presence absence precede myelodysplastic syndrome , blood leukocyte count diagnosis , percentage leukemic cell blood , leukemic cell karyotype .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>patient newly diagnose acute myeloid leukemia ( AML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Chemosensitivity</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>MiCK Assay</keyword>
</DOC>